Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 6:14:695937.
doi: 10.3389/fnmol.2021.695937. eCollection 2021.

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Thomas Leth Jensen  1 , Casper René Gøtzsche  2 , David P D Woldbye  2
Affiliations
Review

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Thomas Leth Jensen et al. Front Mol Neurosci. .

Abstract

In recent years, gene therapy has been raising hopes toward viable treatment strategies for rare genetic diseases for which there has been almost exclusively supportive treatment. We here review this progress at the pre-clinical and clinical trial levels as well as market approvals within diseases that specifically affect the brain and spinal cord, including degenerative, developmental, lysosomal storage, and metabolic disorders. The field reached an unprecedented milestone when Zolgensma® (onasemnogene abeparvovec) was approved by the FDA and EMA for in vivo adeno-associated virus-mediated gene replacement therapy for spinal muscular atrophy. Shortly after EMA approved Libmeldy®, an ex vivo gene therapy with lentivirus vector-transduced autologous CD34-positive stem cells, for treatment of metachromatic leukodystrophy. These successes could be the first of many more new gene therapies in development that mostly target loss-of-function mutation diseases with gene replacement (e.g., Batten disease, mucopolysaccharidoses, gangliosidoses) or, less frequently, gain-of-toxic-function mutation diseases by gene therapeutic silencing of pathologic genes (e.g., amyotrophic lateral sclerosis, Huntington's disease). In addition, the use of genome editing as a gene therapy is being explored for some diseases, but this has so far only reached clinical testing in the treatment of mucopolysaccharidoses. Based on the large number of planned, ongoing, and completed clinical trials for rare genetic central nervous system diseases, it can be expected that several novel gene therapies will be approved and become available within the near future. Essential for this to happen is the in depth characterization of short- and long-term effects, safety aspects, and pharmacodynamics of the applied gene therapy platforms.

Keywords: central nervous system; clinical trials; gene therapy; personalized medicine; rare diseases; spinal cord; spinal muscular atrophy; viral vectors.

PubMed Disclaimer

Conflict of interest statement

DW is co-founder and consultant of CombiGene AB (Lund, Sweden) and CG is employed by UCB Nordic A/S (Copenhagen, Denmark). The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abordo-Adesida E., Follenzi A., Barcia C., Sciascia S., Castro M. G., Lowenstein P. R. (2005). Stability of lentiviral-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther. 16, 741–751. 10.1089/hum.2005.16.741 - DOI - PMC - PubMed
    1. Ahmed S. S., Gao G. (2013). Gene therapy for Canavan's disease takes a step forward. Mol. Ther. 21, 505–506. 10.1038/mt.2013.25 - DOI - PMC - PubMed
    1. Aimiuwu O. V., Fowler A. M., Sah M., Teoh J. J., Kanber A., Pyne N. K., et al. . (2020). RNAi-based gene therapy rescues developmental and epileptic encephalopathy in a genetic mouse model. Mol. Ther. 28, 1706–1716. 10.1016/j.ymthe.2020.04.007 - DOI - PMC - PubMed
    1. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., et al. . (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447–45810.1056/NEJMoa0805817. - DOI - PubMed
    1. Aiuti A., Roncarolo M. G., Naldini L. (2017). Gene therapy for ADA-SCID the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol. Med. 9, 737–740. 10.15252/emmm.201707573 - DOI - PMC - PubMed